Huajun Yang, Zhongliang Li, Beibei Tang, Wanqiu Zhuang, Danting Yan, Frank Xing, and Qian Shi
Most human tumors express CD47 to escape macrophage surveillance. Therefore reinstating macrophage functionality in clearing tumor cells targeting CD47 has become an important strategy in immunotherapy.
CrownBio has profiled a large panel of tumor cell lines to study CD47 levels, and discovered that many tumor cells do not in fact present CD47 on their cell surface, despite gene expression data (e.g. RNAseq data) suggesting that they do.
Now, to further research into novel anti-CD47 agents, robust preclinical platforms including in vitro assays are required. To meet this need, Crown Bioscience has developed a macrophage differentiation system followed by M1/M2 activation.